Altria Group stock: Higher outlook meets smoke-free execution test

Altria raised its 2026 full-year adjusted earnings outlook after reporting third-quarter results on October 29, according to the Altria investor release. On Friday, November 13, Altria Group stock traded at 71.06 euros on Lang & Schwarz at 16:02 CET, 0.42 percent above the Xetra close of Thursday, November 12. The quote was 1.23 percent above the 70.20 euros cited in the own report of November 12.

Higher earnings outlook

Altria now expects 2026 adjusted diluted EPS of 5.66 to 5.74 US dollars, compared with a 2025 adjusted base of 5.42 US dollars. The range implies growth of 4.5 to 6.0 percent. The company said performance through the first nine months and confidence in its full-year plan supported the higher outlook.

Third-quarter net revenue rose 1.0 percent to 6.132 billion US dollars, while revenue net of excise taxes increased 3.6 percent to 5.441 billion US dollars. Adjusted diluted EPS rose 4.8 percent to 1.52 US dollars. Altria notes that adjusted measures exclude special items and are not prepared under GAAP.

Buyback supports capital returns

The board authorized a 1 billion US dollar expansion of the existing share repurchase program, which now expires on December 31, 2027. Altria repurchased 5.9 million shares for 400 million US dollars in the quarter and 11.2 million shares for 735 million US dollars during the first nine months.

The capital-return profile remains a support for the investment case, but it does not remove operating pressure. In the third quarter, domestic cigarette shipment volume fell 2.9 percent, while oral tobacco adjusted operating companies income declined 3.7 percent.

Smoke-free transition remains mixed

The smoke-free portfolio continues to provide growth opportunities. Altria said on! shipment volume rose 13.3 percent to 47.8 million cans in the quarter and that further on! PLUS flavor and nicotine-strength expansion is planned.

For investors, the key issue is whether higher smoke-free volumes can translate into durable segment profit while combustible volumes decline. The raised outlook and expanded buyback improve the near-term capital-return profile, while execution in oral products remains central to the longer-term valuation.

US equities remain linked to the current market reports.

More news and analyses on Altria Group stock.